Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02966145 · ClinicalTrials.gov registry record

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

A clinical trial of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD), sponsored by University of California, San Francisco.

Completed
Registry status
293
Enrollment target
8
Study locations

NCT02966145 is a study of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) that has completed, run by University of California, San Francisco. The registered enrollment target is 293 participants, below the 550-participant average among 4 other Progressive Supranuclear Palsy (PSP) trials with a reported enrollment target (47% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02966145, a study of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD), has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
293 participants
Enrollment target
8
Study locations

Study Summary

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.

Conditions Studied

Progressive Supranuclear Palsy (PSP) Corticobasal Degeneration (CBD) Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Corticobasal Syndrome (CBS) Cortical-basal Ganglionic Degeneration (CBGD) Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)

Interventions

  • OTHER Observational Study

Study Locations (8)

California

  • University of California, San Diego (UCSD) - San Diego
  • University of California, San Francisco (UCSF) - San Francisco

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Harvard University - Massachusetts General Hospital - Charlestown

Minnesota

  • Mayo Clinic - Rochester - Rochester

New York

  • Columbia University - New York

Pennsylvania

  • University of Pennsylvania - Philadelphia

Ontario

  • University of Toronto - Toronto

Trial Details

FieldValue
Enrollment Target 293 participants
Start Date 2016-01
Est. Completion 2024-02-28

Sponsor

University of California, San Francisco

1,713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02966145

The ClinicalTrials.gov registry entry for NCT02966145 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 550-participant average among 4 other Progressive Supranuclear Palsy (PSP) trials with a reported enrollment target (47% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Progressive Supranuclear Palsy (PSP) appearing as the primary indexed condition, and to 1 intervention - of which Observational Study is the first listed.

NCT02966145 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02966145 about?

NCT02966145 is a clinical study titled "4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2". The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of ...

What is the current status of trial NCT02966145?

This trial is currently completed. The enrollment target is 293 participants. The study started on 2016-01. Estimated completion is 2024-02-28.

What conditions does trial NCT02966145 study?

This clinical trial studies the following conditions: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD).

What interventions are being tested in trial NCT02966145?

The interventions under investigation include: Observational Study (OTHER).

Who is sponsoring clinical trial NCT02966145?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02966145 being conducted?

This trial has 8 study locations across California, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Progressive Supranuclear Palsy (PSP)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Progressive Supranuclear Palsy (PSP)

All registered trials for this condition

Corticobasal Degeneration (CBD)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.